After-Hours Stock Movers 10/05: (SCYX) (ZUMZ) (JD) Higher; (ALNY) (IDRA) (MDCO) Lower (more...)

October 5, 2016 6:10 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Today's After-Hours Movers

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) 42.3% LOWER; announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities.

SCYNEXIS, Inc. (Nasdaq: SCYX) 15.6% HIGHER; announced the complete results of its two recently completed Phase 2 studies as well as the closing of a $15 million term loan with Solar Capital Ltd. (Nasdaq: SLRC). In the first study, treatment with oral SCY-078 in patients with vulvovaginal candidiasis (VVC), resulted in significantly better clinical cure rates and fewer recurrences of VVC at the four-month follow-up when compared to the standard of care (oral fluconazole). In the second study, which evaluated oral SCY-078 as a step down therapy in patients with invasive candidiasis, oral SCY-078 achieved the target exposure for efficacy and was well-tolerated.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) 12.6% LOWER; announced that it intends to offer and sell up to $50,000,000 of shares of its common stock in an underwritten public offering. In connection with this offering, Idera expects to grant the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. All of the shares in the offering are to be sold by Idera. Idera intends to use the net proceeds from this offering, together with existing cash, cash equivalents and investments, to advance clinical development of certain of its programs. J.P. Morgan and Goldman, Sachs & Co. are acting as joint bookrunning managers for the offering.

Zumiez Inc. (NASDAQ: ZUMZ) 11.2% HIGHER; announced that total net sales for the five-week period ended October 1, 2016 increased 11.5% to $75.0 million, compared to $67.3 million for the five-week period ended October 3, 2015. The Company's comparable sales increased 6.3% for the five-week period compared to a comparable sales decrease of 1.8% in the year ago period. Based primarily on higher than planned sales quarter-to-date the Company is raising its guidance and now expects fiscal 2016 third quarter net sales in the range of $216 to $217 million and net income per diluted share of approximately $0.29 to $0.30, an increase from the previously issued guidance of net sales in the range of $209 to $213 million and net income per diluted share of approximately $0.21 to $0.26. This guidance is now predicated on a comparable sales increase of approximately 2% for the third quarter.

Medicines Co. (NASDAQ: MDCO) 9.1% LOWER; weaker amid Alnylam Pharmaceuticals news (NASDAQ: JD) 5.5% HIGHER; An amended 13G filing on (NASDAQ: JD) showed Wal-Mart (NYSE: WMT) raised its stake to 265,310,428 shares, or 10.8%. As part of a June agreement between the two, Walmart received 144,952,250 newly issued Class A ordinary shares, amounting to approximately 5 percent of total shares outstanding and the companies partnered in several strategic areas.

Ionis Pharmaceuticals Inc (NASDAQ: IONS) 3.9% LOWER; weaker amid Alnylam Pharmaceuticals news

Arrowhead Pharmaceuticals (NASDAQ: ARWR) 3.6% LOWER; weaker amid Alnylam Pharmaceuticals news

Resources Connection (NASDAQ: RECN) 3.1% LOWER; reported Q1 EPS of $0.15, versus $0.19 reported last year. Revenue for the quarter came in at $143.4 million, versus $148.3 million reported last year. Also, announced the unanticipated retirement of its President and Chief Executive Officer (CEO), Anthony Cherbak, 62, due to health considerations, effective October 7, 2016.

Yum! Brands (NYSE: YUM) 2.2% LOWER; reported Q3 EPS of $1.09, $0.01 worse than the analyst estimate of $1.10. Revenue for the quarter came in at $3.32 billion versus the consensus estimate of $3.49 billion.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

JPMorgan, After-Hours Movers, 13G

Add Your Comment